A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Inclusion Criteria (ALL to be fulfilled): * Patient is willing and able to give informed consent for participation in the study. * Patient is aged 18 years or above. * Diagnosed with any disease sub-type of multiple sclerosis. * Diagnosed with symptomatic spasticity due to multiple sclerosis. * Patient has at least moderate spasticity in the opinion of the investigator. * Patient fulfils at least one of the two criteria below. Subject must be either: * Currently established on a regular dose of anti-spasticity therapy, or * Previously tried and failed anti-spasticity therapy. * Stable medication regimen for at least four weeks prior to study entry, for all medications which may have an effect on spasticity and/or cognition. * If the patient is taking disease modifying medication this must be at a stable dose for three months prior to the initial visit. * Willing and able to comply with all study requirements. * Willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable. * Willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study. Exclusion Criteria (if ANY apply): * Any history or immediate family of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition. * Any concomitant disease or disorder (such as poorly controlle…